Trade SpringWorks Therapeutics, Inc. - SWTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 46.13 |
| Open | 46.09 |
| 1-Year Change | 1.41% |
| Day's Range | 46.09 - 46.17 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 28, 2025 | 46.13 | 0.06 | 0.13% | 46.07 | 46.13 | 46.00 |
| Apr 25, 2025 | 44.67 | -0.08 | -0.18% | 44.75 | 44.86 | 44.12 |
| Apr 24, 2025 | 44.88 | 3.68 | 8.93% | 41.20 | 46.16 | 40.39 |
| Apr 23, 2025 | 41.10 | -0.50 | -1.20% | 41.60 | 41.95 | 40.25 |
| Apr 22, 2025 | 40.38 | 2.23 | 5.85% | 38.15 | 40.61 | 37.45 |
| Apr 21, 2025 | 37.00 | -0.60 | -1.60% | 37.60 | 38.13 | 36.46 |
| Apr 17, 2025 | 37.88 | 0.43 | 1.15% | 37.45 | 38.93 | 37.29 |
| Apr 16, 2025 | 37.68 | 0.44 | 1.18% | 37.24 | 37.81 | 36.03 |
| Apr 15, 2025 | 37.52 | 0.68 | 1.85% | 36.84 | 38.72 | 36.84 |
| Apr 14, 2025 | 37.37 | -0.08 | -0.21% | 37.45 | 37.78 | 35.96 |
| Apr 11, 2025 | 36.41 | 2.25 | 6.59% | 34.16 | 36.47 | 33.48 |
| Apr 10, 2025 | 34.37 | -1.08 | -3.05% | 35.45 | 35.95 | 33.05 |
| Apr 9, 2025 | 37.02 | 2.56 | 7.43% | 34.46 | 38.43 | 32.64 |
| Apr 8, 2025 | 35.66 | -2.89 | -7.50% | 38.55 | 38.55 | 34.99 |
| Apr 7, 2025 | 36.90 | -0.40 | -1.07% | 37.30 | 39.79 | 35.60 |
| Apr 4, 2025 | 39.01 | -2.46 | -5.93% | 41.47 | 41.55 | 38.50 |
| Apr 3, 2025 | 43.02 | -2.07 | -4.59% | 45.09 | 45.78 | 42.95 |
| Apr 2, 2025 | 46.45 | 5.20 | 12.61% | 41.25 | 46.86 | 41.25 |
| Apr 1, 2025 | 41.82 | -1.89 | -4.32% | 43.71 | 44.01 | 40.91 |
| Mar 31, 2025 | 44.10 | -1.49 | -3.27% | 45.59 | 45.64 | 43.76 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
SpringWorks Therapeutics, Inc. Company profile
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. It has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SpringWorks Therapeutics Inc revenues decreased from $35M to $0K. Net loss increased from $45.6M to $173.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Biopharmaceutical segment loss increase from $46.3M to $173.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.05 to -$3.59.
| Industry: | Bio Therapeutic Drugs |
100 Washington Blvd
STAMFORD
CONNECTICUT 06902-9302
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com